Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Retained Earnings (2016 - 2025)

Integra Lifesciences Holdings' Retained Earnings history spans 17 years, with the latest figure at -$30.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 103.2% year-over-year to -$30.1 million; the TTM value through Dec 2025 reached -$30.1 million, down 103.2%, while the annual FY2025 figure was -$30.1 million, 103.2% down from the prior year.
  • Retained Earnings for Q4 2025 was -$30.1 million at Integra Lifesciences Holdings, down from $425.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $943.6 million in Q1 2024 and bottomed at -$50.0 million in Q2 2021.
  • The 5-year median for Retained Earnings is $217.7 million (2022), against an average of $380.5 million.
  • The largest annual shift saw Retained Earnings crashed 247.16% in 2023 before it soared 52649.63% in 2024.
  • A 5-year view of Retained Earnings shows it stood at $698.6 million in 2021, then crashed by 98.53% to $10.3 million in 2022, then plummeted by 247.16% to -$15.1 million in 2023, then skyrocketed by 6322.13% to $939.9 million in 2024, then tumbled by 103.2% to -$30.1 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Retained Earnings are -$30.1 million (Q4 2025), $425.1 million (Q3 2025), and -$30.9 million (Q2 2025).